SG11201809237RA - Oxaborole esters and uses thereof - Google Patents
Oxaborole esters and uses thereofInfo
- Publication number
- SG11201809237RA SG11201809237RA SG11201809237RA SG11201809237RA SG11201809237RA SG 11201809237R A SG11201809237R A SG 11201809237RA SG 11201809237R A SG11201809237R A SG 11201809237RA SG 11201809237R A SG11201809237R A SG 11201809237RA SG 11201809237R A SG11201809237R A SG 11201809237RA
- Authority
- SG
- Singapore
- Prior art keywords
- california
- international
- rule
- ave
- applicant
- Prior art date
Links
- OHENQANLQNOMAO-UHFFFAOYSA-N oxaborole Chemical class O1B=CC=C1 OHENQANLQNOMAO-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 206010001935 American trypanosomiasis Diseases 0.000 abstract 1
- 208000024699 Chagas disease Diseases 0.000 abstract 1
- 241000223109 Trypanosoma cruzi Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- -1 oxaborole ester compounds Chemical class 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662335565P | 2016-05-12 | 2016-05-12 | |
| PCT/IB2017/052522 WO2017195069A1 (en) | 2016-05-12 | 2017-05-01 | Oxaborole esters and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809237RA true SG11201809237RA (en) | 2018-11-29 |
Family
ID=58699201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809237RA SG11201809237RA (en) | 2016-05-12 | 2017-05-01 | Oxaborole esters and uses thereof |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US10562921B2 (ru) |
| EP (2) | EP3578562B1 (ru) |
| JP (2) | JP6715957B2 (ru) |
| KR (2) | KR102231489B1 (ru) |
| CN (2) | CN109503637B (ru) |
| AR (2) | AR108450A1 (ru) |
| AU (2) | AU2017263785B2 (ru) |
| BR (2) | BR122018076188A2 (ru) |
| CA (1) | CA3023490C (ru) |
| CL (2) | CL2018003187A1 (ru) |
| CO (1) | CO2018012077A2 (ru) |
| CR (2) | CR20180502A (ru) |
| DK (1) | DK3578562T3 (ru) |
| EA (2) | EA034415B1 (ru) |
| EC (2) | ECSP18091065A (ru) |
| ES (1) | ES2882782T3 (ru) |
| HK (1) | HK1258717A1 (ru) |
| HU (1) | HUE056320T2 (ru) |
| IL (2) | IL262453A (ru) |
| MA (1) | MA44968A (ru) |
| MX (2) | MX2018013743A (ru) |
| NI (2) | NI201801171A (ru) |
| NZ (1) | NZ746906A (ru) |
| PE (2) | PE20190119A1 (ru) |
| PT (1) | PT3578562T (ru) |
| SG (1) | SG11201809237RA (ru) |
| TN (2) | TN2018000351A1 (ru) |
| TW (1) | TWI629279B (ru) |
| UA (2) | UA121354C2 (ru) |
| UY (2) | UY37236A (ru) |
| WO (1) | WO2017195069A1 (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10070649B2 (en) | 2013-01-30 | 2018-09-11 | Agrofresh Inc. | Volatile applications against pathogens |
| US11039617B2 (en) | 2013-01-30 | 2021-06-22 | Agrofresh Inc. | Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness |
| RS64770B1 (sr) | 2016-03-07 | 2023-11-30 | Agrofresh Inc | Sinergistički postupci upotrebe jedinjenja benzoksaborola i gasova za prezerviranje kao antimikrobnih agenasa za useve |
| UA121354C2 (uk) * | 2016-05-12 | 2020-05-12 | Анакор Фармасутікалз, Інк. | Нові сполуки для лікування паразитарних захворювань |
| WO2019108982A1 (en) | 2017-11-30 | 2019-06-06 | Boragen, Inc. | Benzoxaborole compounds and formulations thereof |
| JP2020180170A (ja) * | 2019-04-23 | 2020-11-05 | 東ソー株式会社 | ハロゲン含有ポリエーテルポリオール組成物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| GB9411587D0 (en) | 1994-06-09 | 1994-08-03 | Zeneca Ltd | Compound, composition and use |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| JO3396B1 (ar) | 2007-06-20 | 2019-10-20 | Anacor Pharmaceuticals Inc | جزيئات صغيرة تحتوي على البورون |
| WO2010045505A1 (en) * | 2008-10-15 | 2010-04-22 | Anacor Pharmaceuticals, Inc | Boron-containing small molecules as anti-protozoal agents |
| WO2010045503A1 (en) * | 2008-10-15 | 2010-04-22 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-protozoal agents |
| AP4039A (en) | 2009-08-14 | 2017-02-28 | Daitao Chen | Boron-containing small molecules as antiprotozoal agents |
| US8933018B2 (en) | 2011-02-07 | 2015-01-13 | Rempex Pharmaceuticals, Inc. | Boron containing polybasic bacterial efflux pump inhibitors and therapeutic uses thereof |
| WO2013050591A2 (en) | 2011-10-07 | 2013-04-11 | Syngenta Participations Ag | Method for protecting useful plants or plant propagation material |
| AR088669A1 (es) | 2011-11-21 | 2014-06-25 | Lilly Co Eli | Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos |
| US8669207B1 (en) * | 2013-01-30 | 2014-03-11 | Dow Agrosciences, Llc. | Compounds and compositions |
| WO2015013318A1 (en) | 2013-07-22 | 2015-01-29 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| JP6499175B2 (ja) | 2013-08-09 | 2019-04-10 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | 三環式ベンゾキサボロール化合物及びその使用 |
| WO2015097276A1 (en) * | 2013-12-23 | 2015-07-02 | Syngenta Participations Ag | Benzoxaborole fungicides |
| EP3337809A1 (en) * | 2015-08-17 | 2018-06-27 | Syngenta Participations Ag | 1-hydroxy-3h-2,1-benzoxaborole derivatives and their use as microbiocides |
| UA121354C2 (uk) * | 2016-05-12 | 2020-05-12 | Анакор Фармасутікалз, Інк. | Нові сполуки для лікування паразитарних захворювань |
-
2017
- 2017-05-01 UA UAA201811418A patent/UA121354C2/uk unknown
- 2017-05-01 CN CN201811522724.7A patent/CN109503637B/zh active Active
- 2017-05-01 KR KR1020187035855A patent/KR102231489B1/ko active IP Right Grant
- 2017-05-01 TN TNP/2018/000351A patent/TN2018000351A1/en unknown
- 2017-05-01 EP EP19180969.8A patent/EP3578562B1/en active Active
- 2017-05-01 JP JP2018559924A patent/JP6715957B2/ja not_active Expired - Fee Related
- 2017-05-01 UA UAA201810456A patent/UA120999C2/uk unknown
- 2017-05-01 PE PE2018002055A patent/PE20190119A1/es unknown
- 2017-05-01 BR BR122018076188A patent/BR122018076188A2/pt not_active Application Discontinuation
- 2017-05-01 HU HUE19180969A patent/HUE056320T2/hu unknown
- 2017-05-01 CR CR20180502A patent/CR20180502A/es unknown
- 2017-05-01 EA EA201892203A patent/EA034415B1/ru unknown
- 2017-05-01 AU AU2017263785A patent/AU2017263785B2/en not_active Ceased
- 2017-05-01 SG SG11201809237RA patent/SG11201809237RA/en unknown
- 2017-05-01 EP EP17722886.3A patent/EP3455227A1/en not_active Withdrawn
- 2017-05-01 WO PCT/IB2017/052522 patent/WO2017195069A1/en active Application Filing
- 2017-05-01 MX MX2018013743A patent/MX2018013743A/es unknown
- 2017-05-01 DK DK19180969.8T patent/DK3578562T3/da active
- 2017-05-01 CN CN201780029103.2A patent/CN109153688A/zh active Pending
- 2017-05-01 CR CR20180560A patent/CR20180560A/es unknown
- 2017-05-01 EA EA201892475A patent/EA036661B1/ru not_active IP Right Cessation
- 2017-05-01 NZ NZ746906A patent/NZ746906A/en not_active IP Right Cessation
- 2017-05-01 TN TNP/2019/000106A patent/TN2019000106A1/en unknown
- 2017-05-01 BR BR122023022427-2A patent/BR122023022427A2/pt unknown
- 2017-05-01 PT PT191809698T patent/PT3578562T/pt unknown
- 2017-05-01 ES ES19180969T patent/ES2882782T3/es active Active
- 2017-05-01 PE PE2019000887A patent/PE20191077A1/es unknown
- 2017-05-01 MA MA044968A patent/MA44968A/fr unknown
- 2017-05-01 CA CA3023490A patent/CA3023490C/en active Active
- 2017-05-01 KR KR1020187035848A patent/KR102243775B1/ko active IP Right Grant
- 2017-05-09 TW TW106115364A patent/TWI629279B/zh not_active IP Right Cessation
- 2017-05-09 US US15/590,159 patent/US10562921B2/en active Active
- 2017-05-10 UY UY0001037236A patent/UY37236A/es unknown
- 2017-05-11 AR ARP170101250A patent/AR108450A1/es unknown
-
2018
- 2018-10-17 IL IL262453A patent/IL262453A/en unknown
- 2018-11-08 CO CONC2018/0012077A patent/CO2018012077A2/es unknown
- 2018-11-09 NI NI2018001171A patent/NI201801171A/es unknown
- 2018-11-09 MX MX2018015410A patent/MX2018015410A/es unknown
- 2018-11-09 NI NI2018001172A patent/NI201801172A/es unknown
- 2018-11-09 CL CL2018003187A patent/CL2018003187A1/es unknown
- 2018-11-16 AU AU2018264116A patent/AU2018264116B2/en not_active Ceased
- 2018-11-20 IL IL263161A patent/IL263161B/en unknown
- 2018-11-22 UY UY0001037980A patent/UY37980A/es unknown
- 2018-11-23 AR ARP180103435A patent/AR113543A2/es unknown
- 2018-11-27 CL CL2018003377A patent/CL2018003377A1/es unknown
- 2018-12-11 EC ECSENADI201891065A patent/ECSP18091065A/es unknown
-
2019
- 2019-01-22 HK HK19101118.4A patent/HK1258717A1/zh unknown
- 2019-01-24 JP JP2019009932A patent/JP6715966B2/ja not_active Expired - Fee Related
- 2019-04-12 EC ECSENADI201926702A patent/ECSP19026702A/es unknown
- 2019-09-24 US US16/580,676 patent/US10882872B2/en active Active
-
2020
- 2020-12-01 US US17/108,066 patent/US11578087B2/en active Active
-
2022
- 2022-12-22 US US18/145,315 patent/US20230132298A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809237RA (en) | Oxaborole esters and uses thereof | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201811074RA (en) | Nant cancer vaccine | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201809299QA (en) | Formulations of an lsd1 inhibitor | |
| SG11201809082WA (en) | Nlrp3 modulators | |
| SG11201908604YA (en) | Fused imidazo-piperidine jak inhibitor compound | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201903483VA (en) | Compositions and methods for treating ezh2-mediated cancer | |
| SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| SG11201809342YA (en) | Pyrimidine compounds as jak kinase inhibitors | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201803834UA (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
| SG11201804395PA (en) | Pharmaceutical compositions comprising levodopa amide and uses thereof | |
| SG11201909837YA (en) | Methods for treating lung disorders | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same |